Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 17, 2024

BUY
$40.25 - $52.99 $63,514 - $83,618
1,578 New
1,578 $65,000
Q4 2022

Jan 30, 2023

BUY
$68.48 - $81.09 $431,834 - $511,353
6,306 Added 20.54%
37,002 $2.66 Million
Q3 2022

Nov 09, 2022

SELL
$0.13 - $76.84 $0 - $537
-7 Reduced 0.02%
30,696 $2.18 Million
Q2 2022

Jul 28, 2022

SELL
$72.62 - $79.98 $582,267 - $641,279
-8,018 Reduced 20.71%
30,703 $2.36 Million
Q1 2022

May 05, 2022

SELL
$61.48 - $73.72 $153,761 - $184,373
-2,501 Reduced 6.07%
38,721 $2.83 Million
Q4 2021

Jan 25, 2022

BUY
$53.63 - $62.52 $179,660 - $209,442
3,350 Added 8.85%
41,222 $2.57 Million
Q3 2021

Nov 08, 2021

BUY
$59.17 - $69.31 $543,298 - $636,404
9,182 Added 32.0%
37,872 $2.24 Million
Q2 2021

Aug 09, 2021

BUY
$61.91 - $67.42 $47,980 - $52,250
775 Added 2.78%
28,690 $1.92 Million
Q1 2021

May 17, 2021

BUY
$59.34 - $66.74 $4,450 - $5,005
75 Added 0.27%
27,915 $1.76 Million
Q4 2020

Mar 31, 2021

BUY
$57.74 - $65.43 $103,874 - $117,708
1,799 Added 6.91%
27,840 $1.73 Million
Q3 2020

Nov 13, 2020

BUY
$57.43 - $63.64 $322,526 - $357,402
5,616 Added 27.5%
26,041 $1.57 Million
Q2 2020

Aug 13, 2020

SELL
$54.82 - $64.09 $167,365 - $195,666
-3,053 Reduced 13.0%
20,425 $1.2 Million
Q1 2020

May 14, 2020

SELL
$46.4 - $67.43 $510,539 - $741,932
-11,003 Reduced 31.91%
23,478 $1.31 Million
Q3 2019

Nov 21, 2019

SELL
$42.77 - $50.71 $23 Million - $27.3 Million
-538,448 Reduced 93.98%
34,481 $2.02 Million
Q3 2019

Nov 15, 2019

BUY
$42.77 - $50.71 $23.1 Million - $27.3 Million
539,082 Added 1592.7%
572,929 $26 Million
Q2 2019

Aug 13, 2019

BUY
$44.62 - $49.34 $1.51 Million - $1.67 Million
33,847 New
33,847 $1.49 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Sws Partners Portfolio

Follow Sws Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sws Partners, based on Form 13F filings with the SEC.

News

Stay updated on Sws Partners with notifications on news.